A G Gravina1, N Prevete2, C Tuccillo1, C De Musis1, L Romano1, A Federico1, A de Paulis3, G D'Argenio4, M Romano1. 1. Hepatogastroenterology Unit, Department of Precision Medicine, University of Campania "Luigi Vanvitelli," Naples, Italy. 2. Department of Translational Medical Sciences (DiSMeT)-University of Naples Federico II and Institute of Endocrinology and Experimental Oncology (IEOS) "G. Salvatore," CNR, Naples, Italy. 3. Department of Translational Medical Sciences (DiSMeT) and Center for Basic and Clinical Immunologic Research (CISI), University of Naples Federico II, Naples, Italy. 4. Gastroenterology Unit, Department of Clinical and Experimental Medicine, University of Naples Federico II, Naples, Italy.
Abstract
BACKGROUND AND AIMS: Hp(2-20), a Helicobacter pylori-derived peptide interacting with N-formyl peptide receptors (FPRs), accelerates the healing of gastric injury in rats. Whether Hp(2-20) affects the recovery of inflamed colonic mucosa is unknown. We evaluated whether Hp(2-20) accelerated the healing of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis and explored the mechanism(s) underlying any such effect. METHODS: Fifteen rats underwent rectal administration of Hp(2-20) 250-500 µg/kg/day, or of its control peptide Hp1 for 10 days, following induction of colitis with TNBS. Macroscopic and histological damage was quantified using predetermined injury scores. FPR1, COX-2, TNF-α, TGF-β, HB-EGF and tissue transglutaminase (t-TG) messenger RNA (mRNA) expression in colonic tissue was determined by quantitative polymerase chain reaction; FPR1, TNF-α and COX-2 protein levels by Western blotting. RESULTS: (1) Hp(2-20) accelerated healing of TNBS-induced colitis compared to controls consistently with the expression of FPRs in colonic mucosa; (2) TNBS upregulated mRNA mucosal expression of COX-2, TNF-α, TGF-β, HB-EGF and t-TG and (3) this, with the exception of HB-EGF, was significantly counteracted by Hp(2-20). CONCLUSIONS: Hp(2-20), an FPR agonist, accelerates the healing of TNBS-induced colitis in the rat. This effect is associated with a significant reduction in colonic tissue levels of COX-2, TGF-β, TNF-α and t-TG. We postulate that FPR-dependent pathways may be involved in the repair of inflamed colonic mucosa.
BACKGROUND AND AIMS: Hp(2-20), a Helicobacter pylori-derived peptide interacting with N-formyl peptide receptors (FPRs), accelerates the healing of gastric injury in rats. Whether Hp(2-20) affects the recovery of inflamed colonic mucosa is unknown. We evaluated whether Hp(2-20) accelerated the healing of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis and explored the mechanism(s) underlying any such effect. METHODS: Fifteen rats underwent rectal administration of Hp(2-20) 250-500 µg/kg/day, or of its control peptide Hp1 for 10 days, following induction of colitis with TNBS. Macroscopic and histological damage was quantified using predetermined injury scores. FPR1, COX-2, TNF-α, TGF-β, HB-EGF and tissue transglutaminase (t-TG) messenger RNA (mRNA) expression in colonic tissue was determined by quantitative polymerase chain reaction; FPR1, TNF-α and COX-2 protein levels by Western blotting. RESULTS: (1) Hp(2-20) accelerated healing of TNBS-induced colitis compared to controls consistently with the expression of FPRs in colonic mucosa; (2) TNBS upregulated mRNA mucosal expression of COX-2, TNF-α, TGF-β, HB-EGF and t-TG and (3) this, with the exception of HB-EGF, was significantly counteracted by Hp(2-20). CONCLUSIONS: Hp(2-20), an FPR agonist, accelerates the healing of TNBS-induced colitis in the rat. This effect is associated with a significant reduction in colonic tissue levels of COX-2, TGF-β, TNF-α and t-TG. We postulate that FPR-dependent pathways may be involved in the repair of inflamed colonic mucosa.
Entities:
Keywords:
Hp(2–20); TNBS colitis; formyl peptide receptors; healing; rat
Authors: C Loguercio; G D'Argenio; M Delle Cave; V Cosenza; N Della Valle; G Mazzacca; C del Vecchio Blanco Journal: Dig Dis Sci Date: 1996-06 Impact factor: 3.199
Authors: Andrei Radulescu; Hong-Yi Zhang; Chun-Liang Chen; Yan Chen; Yu Zhou; Xiaoyi Yu; Iyore Otabor; Jacob K Olson; Gail E Besner Journal: J Surg Res Date: 2010-09-08 Impact factor: 2.192
Authors: Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy Journal: Pharmacol Rev Date: 2009-06-04 Impact factor: 25.468
Authors: Marianne R Spalinger; Thomas Sb Schmidt; Marlene Schwarzfischer; Larissa Hering; Kirstin Atrott; Silvia Lang; Claudia Gottier; Annelies Geirnaert; Christophe Lacroix; Xuezhi Dai; David J Rawlings; Andrew C Chan; Christian von Mering; Gerhard Rogler; Michael Scharl Journal: J Clin Invest Date: 2019-05-20 Impact factor: 14.808
Authors: J Homolak; M Nikolić; D Potoč; M Živković; D Bakula; I Budimir; I Pavić; D Hrabar; N Ljubičić; D Vražić Journal: BMC Gastroenterol Date: 2021-07-31 Impact factor: 3.067